Evidence map›Paper›PMID 28754129›Full record

ArticleVirology journal2017

3-(2-Chloropropyl amide)-4-methoxy-N-phenylbenzamide inhibits expression of HPV oncogenes in human cervical cancer cell.

Fang Han, Yanping Li, Qiaoni Lu, Linlin Ma, Huiqiang Wang, Jiandong Jiang, Zhuorong Li, Yuhuan Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Fang HanInstitute of Medicinal Biotechnology, Chinese Academy of Medical Science & Peking Union Medical College, No 1, Tiantan Xili, Beijing, 100050, People's Republic of China.
Yanping LiInstitute of Medicinal Biotechnology, Chinese Academy of Medical Science & Peking Union Medical College, No 1, Tiantan Xili, Beijing, 100050, People's Republic of China.
Qiaoni LuInstitute of Medicinal Biotechnology, Chinese Academy of Medical Science & Peking Union Medical College, No 1, Tiantan Xili, Beijing, 100050, People's Republic of China.
Linlin MaInstitute of Medicinal Biotechnology, Chinese Academy of Medical Science & Peking Union Medical College, No 1, Tiantan Xili, Beijing, 100050, People's Republic of China.
Huiqiang WangInstitute of Medicinal Biotechnology, Chinese Academy of Medical Science & Peking Union Medical College, No 1, Tiantan Xili, Beijing, 100050, People's Republic of China.
Jiandong JiangInstitute of Medicinal Biotechnology, Chinese Academy of Medical Science & Peking Union Medical College, No 1, Tiantan Xili, Beijing, 100050, People's Republic of China.
Zhuorong LiInstitute of Medicinal Biotechnology, Chinese Academy of Medical Science & Peking Union Medical College, No 1, Tiantan Xili, Beijing, 100050, People's Republic of China. l-z-r@263.net.
Yuhuan LiInstitute of Medicinal Biotechnology, Chinese Academy of Medical Science & Peking Union Medical College, No 1, Tiantan Xili, Beijing, 100050, People's Republic of China. yuhuanlibj@126.com.
Chinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHuman papillomaviruses (HPVs) are the primary causative agents for cervical cancer, and HPV oncoproteins E6 and E7 are known to be the main reason for the onset and maintenance of the malignancies. Therefore, inhibition of viral E6 and E7 oncoproteins expression represents a viable strategy to cervical cancer therapies. This study is to evaluate the antiviral effect of a novel N-Phenylbenzamide derivative, 3-(2-Chloropropyl amide)-4-methoxy-N-phenylbenzamide (L17), against HPV16 in vitro and identify its associated mechanism of action in cervical cancer cells.

methodsThe cytotoxic effect of L17 was assessed by MTT assay. The mRNA and protein levels of E6 and E7 oncogenes were analyzed by quantitative real-time reverse transcription PCR (qRT-PCR) and Western blot, respectively. p53 and Rb protein levels were also detected by Western blot. The effect of L17 on cell cycle was analyzed by flow cytometry.

resultsThe cytotoxic effect of L17 was greater in cervical carcinoma cells than in normal cells. L17 significantly reduced the expression of HPV16 E6 and E7 mRNA and protein, at least partly by enhancing degradation of HPV16 E6 and E7 mRNA. Moreover, reduced expression of E6 and E7 induced by L17 resulted in the up-regulation of p53 and Rb expression, which subsequently induced CaSki cells arrest at G

conclusionsL17 has antiviral activity through suppressing E6 and E7 oncogene expression and could inhibit CaSki cell proliferating by inducing cells arrest at G

Indexed as

Antiviral AgentsBenzamidesBlotting, WesternCell Cycle CheckpointsCell Line, TumorCell ProliferationCell SurvivalFemaleFlow CytometryGene Expression ProfilingGene Expression Regulation, ViralHuman papillomavirus 16HumansOncogene Proteins, ViralPapillomavirus E7 ProteinsReal-Time Polymerase Chain ReactionAntiviral AgentsBenzamidesE6 protein, Human papillomavirus type 16oncogene protein E7, Human papillomavirus type 16Oncogene Proteins, ViralPapillomavirus E7 ProteinsRepressor ProteinsRetinoblastoma ProteinTP53 protein, humanTumor Suppressor Protein p533-(2-Chloropropyl amide)-4-methoxy-N-phenylbenzamideAntiviralCervical carcinomaHuman papillomavirus (HPV) type 16

Identifiers

PMID28754129
PMCPMC5534069
OpenAlexW2740309190

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.